MedTrace Logo

Bowel Function After Minimally Invasive Urogynecologic Surgery

NCT01044212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-10-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effect of a standardized postoperative bowel regimen of over-the-counter medications in subjects undergoing minimally invasive urogynecologic surgery.

Conditions

  • Functional Disorder of Intestine

Interventions

DRUG

Docusate

Docusate 100mg BID

DRUG

Bowel medications

Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Gunhilde Buchsbaum, MD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01044212 on ClinicalTrials.gov